Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. - Wikidata - wikimedia - TriplyDB

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

http://www.wikidata.org/entity/Q33683126

about

PI3K/Akt/mTOR inhibitors in breast cancer The fate of chemoresistance in triple negative breast cancer (TNBC)Triple negative breast cancer: looking for the missing link between biology and treatments Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies Everolimus in the Treatment of Metastatic Breast Cancer Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data.Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.Novel therapeutic strategies in the treatment of triple-negative breast cancer.Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents Triple-negative breast cancer: new perspectives for targeted therapies.SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer Triple-negative breast cancer: an update on neoadjuvant clinical trials.Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.Trends of triple negative breast cancer research (2007-2015): A bibliometric study.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.Clinical development of mTOR inhibitors in breast cancer.Therapies for triple negative breast cancer.New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway.The therapeutic potential of mTOR inhibitors in breast cancer.Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.Safety of mTOR inhibitors in breast cancer.Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials.Signaling pathway profiling using reverse-phase protein array and its clinical applications.Targeting the mTOR pathway in breast cancer.ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.Therapeutic landscape in mutational triple negative breast cancer

P2860

Q26771394-6F04551B-F455-4FCC-AF8D-DB327FBF9930 Q26775232-91F17154-3B03-43C0-8AB9-D20B1C604C7B Q26783122-B9C8B244-8B28-460F-AB44-349DF5935ACF Q26783705-58C7EEC1-92F3-41AD-BC5E-A7FCAB5ED8C5 Q26784920-C1E06F26-C60B-45A0-AFB5-89D561FAAFC0 Q30251429-BC8CA89F-2436-4A73-A9BD-6EA2F962FB5E Q30583249-9665A957-FED4-45E4-8467-C42A5AD821A4 Q31134060-2821AAF8-CFD7-4DBA-9831-A6724B897466 Q33434092-E20EF0A5-D22D-400B-B4B9-2D603E1003EF Q33739184-2DC3FF47-C407-46E3-939C-251D30005A79 Q33887682-78A51EED-9FB4-4141-8E11-99B5807FACFD Q34646376-F984905F-F243-4B12-8266-BC4C6DFBF92F Q35001758-4572C0AB-A015-4DB2-8C50-5336051931AE Q35127249-569AC423-74D6-458F-B615-FC61C8225065 Q35725961-F417E43C-D5BD-418D-93C3-881053371636 Q37105085-AD85B483-9B46-4E92-A2F8-4AA0BD82B2F6 Q37433105-96B1E67B-A1DD-4F32-AF46-675C0BC70195 Q37645090-764FE16E-5F64-4F74-BF80-4768F4F76B96 Q37690076-94EAE829-AE37-4FC2-BD84-190E11395586 Q38424397-3E6CFAA5-C4D0-4AF5-8EA6-0F9D5552E09B Q38604713-665C458A-83A1-44D2-9BC2-70307B44DC99 Q38802412-4F81D12E-0286-4D78-8DE3-9962D9064DE0 Q38825945-DE4E427F-7C85-4BB9-85A7-4519D0F4430A Q38841039-19E1A454-F083-4AB0-BFD6-E0B5524FB6FF Q38882776-FD41D689-09B6-428F-908A-46F265641B41 Q39377837-C9A32241-CB4E-41A6-B0FD-FA2F48B7A20E Q39390640-44D4B4BB-E4A2-4BC3-B9D1-2F81069773F8 Q41674321-D85A09BD-AF05-4101-82E6-BED959838D46 Q47121796-E28637D7-FEAB-417B-B20F-13DBA7475133 Q48551091-0774F3CE-4E44-4237-9E1F-AECDFCA2EE5C Q54965602-6348EA95-1FF9-416E-B07E-3BBBCC947DBC Q55428234-67118859-1AF2-4677-93C2-28AD5865295C Q57109569-185D0B2A-4CED-4805-8DB7-4693746F2082

P2860

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

http://www.wikidata.org/entity/Q33683126

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Open-label randomized clinical ...... eptor-negative breast cancer†.

@ast

Open-label randomized clinical ...... eptor-negative breast cancer†.

@en

type

label

Open-label randomized clinical ...... eptor-negative breast cancer†.

@ast

Open-label randomized clinical ...... eptor-negative breast cancer†.

@en

prefLabel

Open-label randomized clinical ...... eptor-negative breast cancer†.

@ast

Open-label randomized clinical ...... eptor-negative breast cancer†.

@en

P1433

Q33683126-3B35E34B-F3F3-48A9-B0CF-AC7710CA7A31

P1476

Q33683126-88F488E3-0C9A-458E-A432-F7F2D71C661E

P2093

Q33683126-0B22D5B2-E5FD-4C1B-B358-DEEA42D106C3

Q33683126-14E8F55D-4BBE-448E-A70B-6CB69EEC76BD

Q33683126-189B06F2-09FF-41A7-8A7C-A9B064652D43

Q33683126-197B34F5-1AB3-419E-9F10-897847B445DB

Q33683126-2307CA14-6D68-424E-A2D2-1157B4001D9B

Q33683126-25CB1629-8699-4E29-878E-BDC12CA112CE

Q33683126-2A083552-9C8C-42C5-A98A-CBD8F5F2F953

Q33683126-3209A556-07FA-4268-9896-CD5933D6B0F8

Q33683126-3D0CB905-321B-4D76-8A48-51F2998D9642

Q33683126-48628CB1-5ECC-4640-A58C-F8B99EEE8C98

P2860

Q33683126-00A47101-A03D-4325-A0B0-961F20B21904

Q33683126-0E4A9716-F7DD-46EB-A291-89262F5A0BE5

Q33683126-2B4F2A00-FA72-4B98-929C-A66628754EEE

Q33683126-3931C2C0-1D52-4DA8-811D-3C0B421A1F59

Q33683126-3978DB14-8411-48B9-8337-B4E7440892EE

Q33683126-4914AA5A-633B-4A2C-A49F-3E2BE2273B74

Q33683126-5A0339B3-8D3C-4E31-8BAE-BDCF95920EB2

Q33683126-63A43667-A41F-40FE-8A79-89BC57CC6754

Q33683126-716472DA-2EE5-400A-8D68-50B86461841F

Q33683126-814313BC-3B2A-47EB-9027-C9F9AA645851

P304

Q33683126-0D0C1B5B-94A0-4E9E-9825-0C97371E0C76

P31

Q33683126-A5E6C774-461D-455E-879E-E5E0660399F9

P356

Q33683126-05C4A442-EC19-4789-835A-42EE86257D83

P433

Q33683126-9BEA50CF-8468-4DDA-A821-FB3151A7A280

P478

Q33683126-2CF97594-8432-49C8-86E6-D1BD1CD20D72

P50

Q33683126-3DD48523-E300-401C-903D-A3254BDA9EF5

P577

Q33683126-9217A0FC-F127-454A-B60B-98E732957D47

P5875

Q33683126-4C21E3A5-1C27-4FE8-896D-8558969595DA

P698

Q33683126-2DEEE620-1D33-41A5-AD7D-3D6171D5C0AD

P921

Q33683126-8A4C70BC-11C6-4BC1-84C5-0944D389F7F7

Q33683126-F9441F78-B92D-47B0-9BA2-44549E848E9D

P932

Q33683126-2C0411FA-A29B-405A-AFD0-A1C735919CC2

P356

P1433

Annals of Oncology

P1476

Open-label randomized clinical ...... ceptor-negative breast cancer†

@en

P2093

A Akcakanat

http://www.w3.org/2001/XMLSchema#string

A M Brewster

http://www.w3.org/2001/XMLSchema#string

A M Gonzalez-Angulo

http://www.w3.org/2001/XMLSchema#string

A Sahin

http://www.w3.org/2001/XMLSchema#string

D Crawford

http://www.w3.org/2001/XMLSchema#string

E Tarco

http://www.w3.org/2001/XMLSchema#string

F Meric-Bernstam

http://www.w3.org/2001/XMLSchema#string

G B Mills

http://www.w3.org/2001/XMLSchema#string

G N Hortobagyi

http://www.w3.org/2001/XMLSchema#string

H Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

Targeting the mTOR signaling network for cancer therapy

Triple-Negative Breast Cancer

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer.

PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors

Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy

P304

1122-1127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDU124

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Sharon H. Giordano

P577

2014-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261105695

http://www.w3.org/2001/XMLSchema#string

P698

24669015

http://www.w3.org/2001/XMLSchema#string

P921

triple-receptor negative breast cancer

P932

4037860

http://www.w3.org/2001/XMLSchema#string